The Association Between Plasma MicroRNA-451 Expression Levels and Chronic Kidney Disease in Children with
Heba Mostafa Ahmed1, Dina Badea Georgy, Mohamed Hussein Meabed
1Department of Pediatrics, Faculty of Medicine, Beni-Suef University, Egypt. heba_most@yahoo.com.
Introduction:
Patients with β -thalassemia major (β -TM) had a high rate of glomerular dysfunction due to chronic anemia, iron overload, and chelation therapy. There is also evidence of proximal tubular damage, as almost all patients have various amounts of proteinuria. MicroRNAs are non-coding RNA molecules that regulate gene expression. In diabetes, a relative increase in renal microRNA-451 appeared to protect against diabetic kidney injury. This study aimed to investigate the association between miRNA-451 and the development of chronic kidney disease (CKD) in children with β-TM.
Methods:
This study included 60 pediatric patients with β-TM and 30 healthy children as controls. We categorized patients into two groups according to the presence of CKD. Complete blood and reticulocyte counts, serum levels of ferritin, creatinine and glucose, and urine albumin/creatinine ratio (ACR) were measured. Plasma miRNA-451 expression level was measured by real-time quantitative reversed transcription PCR in all included children.
Results:
miRNA-451 levels were significantly higher in β-TM (25.326 ± 12.191) as compared with controls (9.453 ± 5.753) (P < .001). Patients with β-TM and CKD had significantly lower miRNA-451 levels (19.72 ± 13.023) than those without CKD (30.933 ± 8.23). MiRNA-451 levels had significantly positive correlated with eGFR (r = 0.385 P < .05) and reticulocyte counts (r = 0.27, P < .05). Linear logistic regression analysis showed that low plasma microRNA-451 was a significant independent predictor of CKD.
Conclusion:
miRNA-451 has a protective role against CKD development, and low plasma expression levels are associated with CKD in children with β-TM DOI: 10.52547/ijkd.6756.
Insights
Lower levels of microRNA-451 are linked to chronic kidney disease (CKD) in children with beta-thalassemia major (β-TM). This suggests microRNA-451 plays a protective role in preventing kidney damage in these patients.
Area of Science:
- Nephrology
- Genetics
- Pediatrics
Background:
- Beta-thalassemia major (β-TM) patients exhibit high rates of glomerular and proximal tubular dysfunction, leading to chronic kidney disease (CKD).
- MicroRNAs, like microRNA-451, regulate gene expression and have shown protective effects against kidney injury in other conditions, such as diabetes.
Purpose of the Study:
- To investigate the association between microRNA-451 levels and the development of CKD in pediatric patients with β-TM.
Main Methods:
- A case-control study involving 60 children with β-TM and 30 healthy controls.
- Measurement of plasma microRNA-451 levels using real-time quantitative reverse transcription PCR.
- Assessment of clinical parameters including complete blood counts, ferritin, creatinine, glucose, and urine albumin/creatinine ratio (ACR).
Main Results:
- Plasma microRNA-451 levels were significantly higher in β-TM patients compared to controls (P < .001).
- Patients with β-TM and CKD had significantly lower microRNA-451 levels than those without CKD.
- Low plasma microRNA-451 was identified as a significant independent predictor of CKD in β-TM patients.
Conclusions:
- MicroRNA-451 appears to have a protective role in the development of CKD in children with β-TM.
- Reduced plasma microRNA-451 expression is associated with the presence of CKD in this patient population.
Related Concept Videos
01:25Chronic Kidney Disease I: Introduction
01:24Chronic Kidney Disease II: Clinical Manifestations
01:28Kidney Transplant I: Introduction
01:28Chronic Kidney Disease III: Interprofessional Care